Per 21 CFR 1271.155, an HCT/P establishment may request an exemption or alternative procedure to any Donor Eligibility and/or Current Good Tissue Practices regulation. The request for exemption or alternative procedure must be submitted to the appropriate center director at the FDA; however, CBER has redelegated the authority to issue a response to the director and deputy director of the Office of Cellular, Tissue and Gene Therapies. The request must include supporting documentation, including all relevant valid scientific data, and must contain either information justifying the requested exemption from the requirement or a description of a proposed alternative method of meeting the requirement. Additional information on requesting an exemption or alternative procedure is available.
HHS Seeks Input on Regulating Deceased-Donor Islet Cell Therapies
September 23, 2026
AABB2026: AABB Welcomes Additional Organizations to 2026 Biotherapies Pavilion
September 22, 2026
AABB Publishes New Biotherapies Manual
September 18, 2026